These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16640533)

  • 21. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Impact of pulmonary hypertension on early hemodynamics after orthotopic heart transplantation].
    Liu MZ; Wang JH; Du J; Huang J; Li LH
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2618-22. PubMed ID: 18162149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of bosentan on pulmonary hypertension secondary to systolic heart failure.
    Padeletti M; Caputo M; Zacà V; Tsioulpas C; Bernazzali S; Mondillo S; Maccherini M; Jelic S
    Pharmacology; 2013; 92(5-6):281-5. PubMed ID: 24296902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Iloprost improves hemodynamics in patients with severe chronic cardiac failure and secondary pulmonary hypertension.
    Sablotzki A; Czeslick E; Schubert S; Friedrich I; Mühling J; Dehne MG; Grond S; Hentschel T
    Can J Anaesth; 2002 Dec; 49(10):1076-80. PubMed ID: 12477682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial.
    Baughman RP; Culver DA; Cordova FC; Padilla M; Gibson KF; Lower EE; Engel PJ
    Chest; 2014 Apr; 145(4):810-817. PubMed ID: 24177203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates.
    Salzberg SP; Lachat ML; von Harbou K; Zünd G; Turina MI
    Eur J Cardiothorac Surg; 2005 Feb; 27(2):222-5. PubMed ID: 15691674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M; Romeo E; Argiento P; Santoro G; Sarubbi B; Gaio G; Mélot C; Russo MG; Naeije R; Calabrò R
    Heart; 2010 Sep; 96(18):1475-9. PubMed ID: 20668108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates.
    Radovancevic B; Vrtovec B; Thomas CD; Croitoru M; Myers TJ; Radovancevic R; Khan T; Massin EK; Frazier OH
    J Heart Lung Transplant; 2005 Jun; 24(6):690-5. PubMed ID: 15949728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Short-term survival after heart transplantation: the relationships between preoperative hemodynamics, organ function and postoperative clinical events].
    Frigerio M; Gronda E; Danzi GB; Mangiavacchi M; Oliva F; Quaini E; Trotta E; De Vita C; Pellegrini A
    G Ital Cardiol; 1995 Jan; 25(1):1-9. PubMed ID: 7642005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Left Ventricular Assist Devices or Inotropes for Decreasing Pulmonary Vascular Resistance in Patients with Pulmonary Hypertension Listed for Heart Transplantation.
    Al-Kindi SG; Farhoud M; Zacharias M; Ginwalla MB; ElAmm CA; Benatti RD; Oliveira GH
    J Card Fail; 2017 Mar; 23(3):209-215. PubMed ID: 27374840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between two drugs on the hemodynamic evaluation of pulmonary hypertension prior to heart transplantation.
    Mogollón Jiménez MV; Escoresca Ortega AM; Hinojosa Pérez R; Lage Gallé E; Herruzo Avilés A; Sobrino Márquez M; Frutos López M; Romero Rodríguez N; Pérez de la Yglesia R; Martínez Martínez A
    Transplant Proc; 2008 Nov; 40(9):3009-11. PubMed ID: 19010174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initial experience with bosentan for the management of pulmonary hypertension after heart transplantation.
    Santiago-Vacas E; Farrero M; Ivey-Miranda JB; Castel MÁ; García-Álvarez A; Rios J; Perez-Villa F
    Clin Transplant; 2018 Sep; 32(9):e13364. PubMed ID: 30058129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
    Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
    Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated pulmonary vascular resistance and cardiac transplantation.
    Addonizio LJ; Gersony WM; Robbins RC; Drusin RE; Smith CR; Reison DS; Reemtsma K; Rose EA
    Circulation; 1987 Nov; 76(5 Pt 2):V52-5. PubMed ID: 3311456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates.
    Zakliczynski M; Maruszewski M; Pyka L; Trybunia D; Nadziakiewicz P; Przybylski R; Zembala M
    Transplant Proc; 2007 Nov; 39(9):2856-8. PubMed ID: 18022001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of treatment with a combination of cardiac rehabilitation and bosentan in patients with pulmonary Langerhans cell histiocytosis associated with pulmonary hypertension.
    Fukuda Y; Miura S; Fujimi K; Yano M; Nishikawa H; Yanagisawa J; Hiratsuka M; Shiraishi T; Iwasaki A; Saku K
    Eur J Prev Cardiol; 2014 Dec; 21(12):1481-3. PubMed ID: 23897898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.